| Reductions in medications with substantial weight loss with behavioral intervention. | |
| | |
MedLine Citation:
|
PMID: 20925648 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Medical costs of obesity in the United States exceed $147 billion annually with medication costs making a sizable contribution. We examined medication costs associated with substantial weight losses in an intensive behavioral weight loss program. Inclusion criteria were medication use for obesity co-morbidities: hypertension, diabetes, dyslipidemia, degenerative joint disease, or gastroesophageal reflux disease. Group A, 83 obese patients on medications completed 8 weeks of classes, lost 19 kg in 20 weeks. Group B, 100 severely obese patients, lost 59 kg in 45 weeks. Medications were discontinued: Group A, 18%; Group B, 64%. Mean numbers of medications decreased significantly for all co-morbidities. Mean numbers of daily medications, initial and final, respectively were: Group A, total, 3.0 ± 0.2 (mean ± SEM) and 1.7 ± 0.2; Group B, total, 2.5 ± 0.2 and 0.7 ± 0.1. Monthly costs for all medications decreased significantly for all co-morbidities and were as follows: Group A, total, $249 ± 25 and $153 ± 19; Group B: total, $237 ± 27 and $65 ± 12. Medically supervised weight loss is very effective approach for improving cardiovascular risk factors and reducing medical costs. |
| | |
Authors:
|
James W Anderson; Manan A Jhaveri |
Related Documents
:
|
20951418 - Trends in the medical management of urolithiasis: a comparison of general urologists an... 10119378 - Structuring group medical practices: tax planning aspects. 7289678 - Psychotropic drugs in the ambulatory care of elderly males. 14680718 - Sexual dysfunction among patients treated with antidepressants--a hungarian retrospecti... 22073498 - Prevalence of methicillin resistant staphylococcus aureus in nasal samples from preclin... 1578428 - A decade of experience of examining candidates for entry to the army. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current clinical pharmacology Volume: 5 ISSN: 1574-8847 ISO Abbreviation: Curr Clin Pharmacol Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-12 Completed Date: 2011-03-01 Revised Date: 2011-09-06 |
Medline Journal Info:
|
Nlm Unique ID: 101273158 Medline TA: Curr Clin Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 232-8 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine and Clinical Nutrition, University of Kentucky, 913 Taborlake Court, Lexington, KY 40502, USA. jwandersmd@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
economics,
therapeutic use Behavior Therapy* Diabetes Mellitus / drug therapy, economics Drug Costs / statistics & numerical data* Dyslipidemias / economics, prevention & control Humans Hypertension / drug therapy, economics Hypoglycemic Agents / economics, therapeutic use Hypolipidemic Agents / economics, therapeutic use Obesity / economics*, psychology* Risk Factors Weight Loss* |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Hypoglycemic Agents; 0/Hypolipidemic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical pharmacokinetics of ibuprofen arginine.
Next Document: Fibrosis in the anterior segments of the eye.